Early-stage decisions that shape cell therapy development

Early-stage cell therapy companies face a series of process, workflow, and platform decisions well before IND, and each one shapes the likelihood of a successful clinical program. This panel discussion examines those decisions and the trade-offs behind them across various modalities, such as CAR-T, TIL, TCR, NK cell, and HSC-based therapies.

Drawing on real-world examples, the panel explains how early technical choices affect comparability risk, regulatory expectations, and development timelines. Speakers discuss what drives platform and workflow evaluation at each stage, the challenges that arise as processes evolve, and how today's decisions can either preserve or limit future flexibility.

View this webinar to:
• See how early technical decisions shape timelines, readiness, and investor confidence
• Get a practical framework for smarter development decisions
• Learn when to evaluate process, workflow, and platform options, before timing costs you

Speakers:
• Jeff Liter, CEO, Luminary Therapeutics
• Motjaba Parvizi, Global FastTrak Director, Cell Therapy, Cytiva
• Mo Heidaran, Chief Regulatory Scientist, Cellx Consulting

Explore how Cytiva can help you reduce variability, accelerate clinical progress, and de-risk scale-up for your cell therapy: https://cytiva.link/g7rmq